Innocan Pharma Corporation (CSE: INNO) has announced the closing of the first tranche of a private placement, issuing 247,314 units at C$1.87 per unit for gross proceeds of C$462,477. The offering, which was first disclosed on September 9, 2026, includes both common shares and warrants exercisable at C$2.50. The raise provides the Israel- and Calgary-based pharmaceuticals and wellness company with additional working capital and highlights continued financing activity on the Canadian Securities Exchange.

Key Points

  • Innocan Pharma Corporation (CSE: INNO, FSE: IP4, OTC: INNPF) announced the first tranche closing of a private placement
  • 247,314 units were issued at C$1.87 per unit, generating gross proceeds of C$462,477
  • Each unit consists of one common share and one warrant exercisable at C$2.50 for three years, with an acceleration clause triggering at a 30-consecutive-day volume-weighted average price of C$4.80 or above
  • Investors may be watching for potential additional tranches of the offering and deployment of proceeds toward working capital

Unit Structure and Warrant Acceleration Terms

Each unit issued in the offering comprises one common share and one common share purchase warrant. The warrants entitle holders to acquire one additional common share at C$2.50 for a period of three years from the date of issuance. Notably, the release states that if the daily volume-weighted average trading price of Innocan's common shares on the Canadian Securities Exchange equals or exceeds C$4.80 for 30 consecutive trading days, the company may accelerate the warrant expiry to 30 days following issuance of an acceleration notice to subscribers.

Use of Proceeds and Finder's Fees

Innocan disclosed that proceeds from the offering will be directed toward working capital and general corporate purposes. The company also paid finders' fees in connection with the placement, comprising a cash component equal to 10% of applicable proceeds and finder's warrants representing 8% of the units placed through arm's-length finders. These terms are standard for brokered or finder-assisted private placements under Canadian securities regulations. Securities issued in the offering are subject to a statutory hold period of four months and one day from the date of issuance.

Innocan's Pharmaceuticals and Wellness Business Profile

Innocan operates across the pharmaceuticals and wellness sectors, with a self-care and beauty product portfolio marketed through its 60%-owned subsidiary, BI Sky Global Ltd. The subsidiary focuses on advanced targeted online sales. The company is headquartered across Herzliya, Israel, and Calgary, Alberta, and trades on three exchanges: the CSE, the Frankfurt Stock Exchange, and the OTC market. The company did not disclose updated revenue figures or operational metrics in this announcement.